Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during...

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• CD8(+) T cells are crucial for anti-tumor immunity but often become dysfunctional in cancer patients.
• Understanding the early onset and drivers of T cell dysfunction is critical for improving cancer immunotherapy.
• Existing models lack the ability to track tumor-specific T cell dynamics during tumorigenesis.

Purpose of the Study:

• To investigate the early activation, differentiation, and dysfunction of tumor-specific CD8(+) T cells (TST cells) during cancer development.
• To determine the reversibility of TST cell dysfunction and identify its underlying causes.
• To differentiate TST cell dysfunction from T cell exhaustion observed in chronic infections.

Main Methods:

• Development of a tamoxifen-inducible liver cancer mouse model expressing a defined oncogenic antigen (SV40 large T-antigen).
• Tracking and analysis of naive TST cell activation, differentiation, and functional states post-tumor initiation.
• Phenotypic, functional, and transcriptional profiling of TST cells during pre-malignant and tumor progression phases.
• Assessment of therapeutic reversibility and the impact of persistent antigen exposure versus tumor microenvironment factors.

Main Results:

• TST cells exhibited early-onset dysfunction during the pre-malignant phase, mirroring features of late-stage human tumor-infiltrating T cells.
• The dysfunctional state was initially reversible but evolved into a fixed, irreversible state.
• Persistent antigen exposure was identified as the primary driver of TST cell dysfunction, not the tumor microenvironment.
• The TST cell dysfunction program showed distinct characteristics compared to T cell exhaustion in chronic infections.

Conclusions:

• T cell dysfunction in cancer may be established much earlier in tumorigenesis than previously thought.
• Antigen-driven, cell-intrinsic dysfunction represents a significant barrier to effective cancer immunotherapy.
• Targeting this early-onset, antigen-driven dysfunction is crucial for developing more effective cancer immunotherapies.